Mandate

Vinge advises Bridgepoint in conjunction with its investment in Vitamin Well

November 29, 2016

Vinge has advised Bridgepoint Development Capital in conjunction with its investment in Vitamin Well AB. Vitamin Well AB is a leading Nordic company within functional drinks, which develops, markets and sells high-quality drinks under the well-known trademarks Vitamin Well, Vitamin Well Free, NOBE aloe vera, NOCCO and the sports drink Vitamin Well+.

Following its formation in 2006, Vitamin Well AB has had the vision of being the best and the tastiest functional drinks manufacturer, adapted for various different target groups and situations. Vitamin Well has its headquarters in Stockholm, employs 84 persons and its drinks are sold in 28 countries. The transaction is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consists of partner Daniel Rosvall together with, among others, associates Samra Baytar and Ilze Lukins (M&A), Tomas Forsgren (intellectual property), Lisa Sennerby (employment), Kristoffer Larson (real estate), Albert Wållgren and Karl Klackenberg (banking & finance) and counsel Johan Cederblad (regulatory issues). Grant McKelvey and Marita Ljunggren are advising on competition law notification issues.

 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024